Access the full text.
Sign up today, get DeepDyve free for 14 days.
S. Buys, J. Sandbach, A. Gammon, G. Patel, J. Kidd, K. Brown, L. Sharma, J. Saam, J. Lancaster, M. Daly (2017)A study of over 35,000 women with breast cancer tested with a 25‐gene panel of hereditary cancer genes
Sue Richards, Nazneen Aziz, S. Bale, D. Bick, Soma Das, J. Gastier-Foster, W. Grody, M. Hegde, E. Lyon, E. Spector, K. Voelkerding, H. Rehm (2015)Standards and Guidelines for the Interpretation of Sequence Variants: A Joint Consensus Recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology
Genetics in medicine : official journal of the American College of Medical Genetics, 17
M. Nelen, H. Kremer, I. Konings, F. Schoute, A. Essen, R. Koch, C. Woods, J. Fryns, B. Hamel, L. Hoefsloot, E. Peeters, G. Padberg (1999)Novel PTEN mutations in patients with Cowden disease: absence of clear genotype–phenotype correlations
European Journal of Human Genetics, 7
(2009)Beyond li fraumeni syndrome: clinical 149 A pilot study investigating feasibility of mainstreaming germline BRCA1 and BRCA2 testing... 1 3 characteristics of families with p53 germline mutations
T. Golan, P. Hammel, M. Reni, E. Cutsem, T. Macarulla, M. Hall, Joon-Oh Park, D. Hochhauser, D. Arnold, D. Oh, A. Reinacher-Schick, G. Tortora, H. Algül, E. O’Reilly, D. McGuinness, K. Cui, K. Schlienger, G. Locker, H. Kindler (2019)Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer.
The New England journal of medicine
K. Bokkers, R. Zweemer, M. Koudijs, S. Stehouwer, M. Velthuizen, E. Bleiker, M. Ausems (2021)Positive experiences of healthcare professionals with a mainstreaming approach of germline genetic testing for women with ovarian cancer
Familial Cancer, 21
(2022)HSE National Cancer Control Programme BRCA Testing (PARP Inhibitors)
M. Hussain, J. Mateo, K. Fizazi, F. Saad, N. Shore, S. Sandhu, K. Chi, O. Sartor, N. Agarwal, D. Olmos, A. Thiery-Vuillemin, P. Twardowski, N. Mehra, C. Goessl, Jinyu Kang, J. Burgents, Wenting Wu, A. Kohlmann, C. Adelman, J. Bono (2019)PROfound: Phase III study of olaparib versus enzalutamide or abiraterone for metastatic castration-resistant prostate cancer (mCRPC) with homologous recombination repair (HRR) gene alterations
Annals of Oncology
D. Maiese, Alisha Keehn, Megan Lyon, D. Flannery, M. Watson (2019)Current conditions in medical genetics practice
Genetics in Medicine, 21
Nikolai Sæther, E. Skuja, A. Irmejs, J. Maksimenko, E. Miklaševičs, G. Purkalne, J. Gardovskis (2018)Platinum-based neoadjuvant chemotherapy in BRCA1-positive breast cancer: a retrospective cohort analysis and literature review
Hereditary Cancer in Clinical Practice, 16
M. O'Shea, C. Collins (2016)A survey of GP experience with the work of the National Cancer Control Programme and their views in relation to service priorities
E. Mazzola, A. Blackford, G. Parmigiani, S. Biswas (2015)Recent Enhancements to the Genetic Risk Prediction Model BRCAPRO
Cancer Informatics, 14
D. Evans, F. Lalloo, A. Wallace, N. Rahman (2005)Update on the Manchester Scoring System for BRCA1 and BRCA2 testing
Journal of Medical Genetics, 42
M. Mirza, B. Monk, J. Herrstedt, A. Oza, S. Mahner, A. Redondo, M. Fabbro, J. Ledermann, D. Lorusso, I. Vergote, N. Ben-Baruch, C. Marth, R. Mądry, R. Christensen, J. Berek, A. Dørum, A. Tinker, A. Bois, A. González-Martín, P. Follana, B. Benigno, P. Rosenberg, L. Gilbert, B. Rimel, J. Buscema, J. Balser, S. Agarwal, U. Matulonis (2016)Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer.
The New England journal of medicine, 375 22
L. Henneman, E. Vermeulen, C. El, L. Claassen, D. Timmermans, M. Cornel (2012)Public attitudes towards genetic testing revisited: comparing opinions between 2002 and 2010
European Journal of Human Genetics, 21
J. Weitzel, V. Lagos, C. Cullinane, P. Gambol, Julie Culver, K. Blazer, M. Palomares, K. Lowstuter, D. Macdonald (2007)Limited family structure and BRCA gene mutation status in single cases of breast cancer.
JAMA, 297 23
R. Manchanda, Shreeya Patel, A. Antoniou, E. Levy-Lahad, C. Turnbull, G. Evans, J. Hopper, R. MacInnis, U. Menon, I. Jacobs, R. Legood (2017)Cost‐effectiveness of population based BRCA testing with varying Ashkenazi Jewish ancestry
American Journal of Obstetrics and Gynecology, 217
Aung Win, M. Jenkins, J. Dowty, A. Antoniou, Andrew Lee, G. Giles, D. Buchanan, M. Clendenning, C. Rosty, D. Ahnen, S. Thibodeau, G. Casey, S. Gallinger, L. Marchand, R. Haile, J. Potter, Yingye Zheng, N. Lindor, P. Newcomb, J. Hopper, R. MacInnis (2016)Prevalence and Penetrance of Major Genes and Polygenes for Colorectal Cancer
Cancer Epidemiology, Biomarkers & Prevention, 26
D. Evans, F. Lalloo, A. Cramer, Elizabeth Jones, F. Knox, E. Amir, A. Howell, G. Evans, E. Jones (2009)Addition of pathology and biomarker information significantly improves the performance of the Manchester scoring system for BRCA1 and BRCA2 testing
Journal of Medical Genetics, 46
(2017)National Cancer Strategy 2017–2026, An Roinn Sláinte. Available from: https:// www. gov. ie/ en/ publi cation/ a89819- natio nal- cancer- strat egy
T. Pal, D. Agnese, M. Daly, A. Spada, J. Litton, M. Wick, S. Klugman, E. Esplin, G. Jarvik (2019)Points to consider: is there evidence to support BRCA1/2 and other inherited breast cancer genetic testing for all breast cancer patients? A statement of the American College of Medical Genetics and Genomics (ACMG)
Genetics in Medicine, 22
D. Evans, A. Howell, D. Ward, F. Lalloo, J. Jones, D. Eccles (2011)Prevalence of BRCA1 and BRCA2 mutations in triple negative breast cancer
Journal of Medical Genetics, 48
(2021)The unmet need in cancer genetic services: conducting an environmental scan of the cancer genetics services in an Irish context underpinned by a mixed methods approach
R. Miller, A. Leary, C. Scott, V. Serra, C. Lord, D. Bowtell, D. Chang, D. Garsed, J. Jonkers, J. Ledermann, S. Nik-Zainal, I. Ray-Coquard, S. Shah, X. Matías-Guiu, E. Swisher, L. Yates (2020)ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancer.
Annals of oncology : official journal of the European Society for Medical Oncology
M. Coakley, Vicki Cleary, N. Power, S. O'Reilly (2017)BRCA1/2 germline testing in non-mucinous epithelial ovarian carcinoma: changing international practice and implications for service provision
European Journal of Human Genetics, 25
A George (2016)10.1038/srep29506
Sci Rep, 6
(2016)Lynparza approved in the US as adjuvant treatment for patients with germline BRCA - mutated HER 2 - negative high - risk early breast cancer
CLINICAL MANAGEMENT GUIDELINES FOR OBSTETRICIAN – GYNECOLOGISTS
N. Flaum, Robert Morgan, G. Burghel, M. Bulman, A. Clamp, J. Hasan, Claire Mitchell, D. Badea, Sarah Moon, M. Hogg, D. Hadjiyiannakis, T. Clancy, H. Schlecht, E. Woodward, Emma Crosbie, Richard Edmondson, A. Wallace, G. Jayson, F. Lalloo, E. Harkness, D. Evans (2020)Mainstreaming germline BRCA1/2 testing in non-mucinous epithelial ovarian cancer in the North West of England
European Journal of Human Genetics, 28
P. Beitsch, P. Whitworth, K. Hughes, Rakesh Patel, B. Rosen, G. Compagnoni, P. Baron, R. Simmons, L. Smith, I. Grady, M. Kinney, C. Coomer, K. Barbosa, D. Holmes, E. Brown, L. Gold, Patricia Clark, L. Riley, S. Lyons, A. Ruíz, S. Kahn, H. Macdonald, L. Curcio, M. Hardwick, Shan Yang, E. Esplin, R. Nussbaum (2018)Underdiagnosis of Hereditary Breast Cancer: Are Genetic Testing Guidelines a Tool or an Obstacle?
Journal of Clinical Oncology, 37
Springer Nature or its licensor holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s)
Brittany Jenkins, Catherine Fischer, Courtney Polito, D. Maiese, Alisha Keehn, Megan Lyon, M. Edick, Matthew Taylor, H. Andersson, J. Bodurtha, M. Blitzer, M. Muenke, M. Watson (2021)The 2019 US medical genetics workforce: a focus on clinical genetics
Genetics in Medicine, 23
Mark Robson, Elżbieta Senkus, Binghe Xu, S. Domchek, N. Masuda, S. Delaloge, Nadine Tung, Anne Armstrong, Wenting Wu, Carsten Goessl, S. Runswick, Pierfranco Conte (2017)Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation.
The New England journal of medicine, 377 17
R. Irwin, A. Caffrey, K. Pentieva, S. Minguzzi, J. Brosnan, M. Brosnan, A. Parle‐McDermott, S. O'reilly, W. Bodmer, K. Hutnik, Jf Wilson, G. Cavalleri (2019)21st Meeting of the Irish Society of Human Genetics
The Ulster Medical Journal, 88
N. Percival, A. George, Jennifer Gyertson, M. Hamill, A. Fernandes, E. Davies, N. Rahman, Susana Banerjee (2016)The integration of BRCA testing into oncology clinics.
British journal of nursing, 25 12
P. Ra, A. Mp, Ardinger Hh, Wallace Se, A. Amemiya, Bean Ljh, Bird Td, Fong Ct, Mefford Hc, Smith Rjh, K. Stephens (2016)Peutz-Jeghers Syndrome -- GeneReviews(®)
Mph MD, MS MPH, Mph MD, Keelia Rhoads, Salina Chan, T. Ms, R. Ms, PhD MD, B. Ms, P. Marcom, Mph MD (2013)Prevalence of BRCA Mutations Among Women with Triple-Negative Breast Cancer (TNBC) in a Genetic Counseling Cohort
Annals of Surgical Oncology, 20
S. Lynch, I. Borg (2015)Wide disparity of clinical genetics services and EU rare disease research funding across Europe
Journal of Community Genetics, 7
Sunita Desai, A. Jena (2016)Do celebrity endorsements matter? Observational study of BRCA gene testing and mastectomy rates after Angelina Jolie’s New York Times editorial
The BMJ, 355
K. Metcalfe, S. Narod, A. Eisen, J. Lerner-Ellis (2016)Treatment decision making and psychosocial outcomes associated with rapid genetic testing for BRCA1 and BRCA2 in women newly diagnosed with breast cancer.
Journal of Clinical Oncology, 34
J. Mateo, N. Porta, D. Bianchini, U. McGovern, T. Elliott, Robert Jones, I. Syndikus, C. Ralph, S. Jain, M. Varughese, O. Parikh, S. Crabb, A. Robinson, D. McLaren, A. Birtle, J. Tanguay, S. Miranda, I. Figueiredo, G. Seed, C. Bertan, P. Flohr, Berni Ebbs, P. Rescigno, Gemma Fowler, A. Ferreira, R. Riisnaes, Rita Pereira, A. Curcean, R. Chandler, M. Clarke, B. Gurel, M. Crespo, Daniel Rodrigues, S. Sandhu, A. Espinasse, P. Chatfield, N. Tunariu, W. Yuan, E. Hall, S. Carreira, J. Bono (2019)Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial
The Lancet. Oncology, 21
Nick Dragojlovic, K. Borle, Nicola Kopac, U. Ellis, P. Birch, S. Adam, J. Friedman, A. Nisselle, Nick Lynd, Nick Dragojlovic, P. Birch, S. Adam, J. Friedman, Alison Elliott, L. Lynd, Alison Elliott, L. Lynd (2020)The composition and capacity of the clinical genetics workforce in high-income countries: a scoping review
Genetics in Medicine
SK Sandhu (2019)10.1093/annonc/mdz446.007
Ann Oncol, 30
A. Tutt, J. Garber, B. Kaufman, G. Viale, D. Fumagalli, P. Rastogi, R. Gelber, E. Azambuja, A. Fielding, J. Balmaña, S. Domchek, K. Gelmon, S. Hollingsworth, L. Korde, B. Linderholm, H. Bandos, E. Senkus, J. Suga, Z. Shao, A. Pippas, Z. Nowecki, T. Huzarski, P. Ganz, P. Lucas, N. Baker, S. Loibl, R. McConnell, M. Piccart, R. Schmutzler, G. Steger, J. Costantino, A. Arahmani, N. Wolmark, E. McFadden, V. Karantza, S. Lakhani, G. Yothers, C. Campbell, C. Geyer (2021)Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer.
The New England journal of medicine
(2016)eUpdate-ovarian cancer treatment recommendations
Vera Witjes, M. Bommel, M. Ligtenberg, J. Vos, M. Mourits, M. Ausems, J. Hullu, T. Bosse, N. Hoogerbrugge (2021)Probability of detecting germline BRCA1/2 pathogenic variants in histological subtypes of ovarian carcinoma. A meta-analysis.
K. Maxwell, S. Domchek, K. Nathanson, M. Robson (2016)Population Frequency of Germline BRCA1/2 Mutations.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 34 34
E. Copson, T. Maishman, W. Tapper, R. Cutress, S. Greville-Heygate, S. Greville-Heygate, D. Altman, B. Eccles, S. Gerty, L. Durcan, L. Jones, David Evans, A. Thompson, P. Pharoah, D. Easton, A. Dunning, A. Hanby, S. Lakhani, R. Eeles, F. Gilbert, H. Hamed, S. Hodgson, P. Simmonds, L. Stanton, D. Eccles, D. Eccles (2018)Germline BRCA mutation and outcome in young-onset breast cancer (POSH): a prospective cohort study
The Lancet. Oncology, 19
(2017)The society of gynaecologic oncology of canada (GOC) position statement: no woman left behind: toward a pan-canadian strategy for universal BRCA testing in ovarian cancer
E. Grindedal, K. Jørgensen, P. Olsson, B. Gravdehaug, H. Lurås, E. Schlichting, Tone Vamre, T. Wangensteen, Cecilie Heramb, L. Mæhle (2019)Mainstreamed genetic testing of breast cancer patients in two hospitals in South Eastern Norway
Familial Cancer, 19
Z. Kemp, Alice Turnbull, Shawn Yost, S. Seal, S. Mahamdallie, E. Poyastro-Pearson, M. Warren-Perry, A. Eccleston, Min-Min Tan, S. Teo, N. Turner, Ann Strydom, A. George, N. Rahman (2019)Evaluation of Cancer-Based Criteria for Use in Mainstream BRCA1 and BRCA2 Genetic Testing in Patients With Breast Cancer
JAMA Network Open, 2
B. Rahman, A. Lanceley, R. Kristeleit, J. Ledermann, M. Lockley, M. McCormack, T. Mould, L. Side (2018)Mainstreamed genetic testing for women with ovarian cancer: first-year experience
Journal of Medical Genetics, 56
T. Carver, Simon Hartley, Andrew Lee, A. Cunningham, S. Archer, Chantal Villiers, Jonathan Roberts, Rod Ruston, F. Walter, M. Tischkowitz, D. Easton, A. Antoniou (2020)CanRisk Tool—A Web Interface for the Prediction of Breast and Ovarian Cancer Risk and the Likelihood of Carrying Genetic Pathogenic Variants
Cancer Epidemiology, Biomarkers & Prevention, 30
P. Škerl, M. Krajc, A. Blatnik, S. Novaković (2017)Genetic testing and counseling of a recipient after bone marrow transplant from a sibling harboring a germline BRCA1 pathogenic mutation.
Oncology reports, 38 1
I. Vergote, Susana Banerjee, A. Gerdes, C. Asperen, C. Marth, F. Vaz, I. Ray-Coquard, D. Stoppa-Lyonnet, A. González-Martín, J. Sehouli, N. Colombo (2016)Current perspectives on recommendations for BRCA genetic testing in ovarian cancer patients.
European journal of cancer, 69
A. Poveda, A. Floquet, J. Ledermann, R. Asher, R. Penson, A. Oza, J. Korach, T. Huzarski, S. Pignata, M. Friedlander, Alessandra Baldoni, T. Park-Simon, G. Sonke, A. Lisyanskaya, Jae Kim, E. Filho, I. Vergote, P. Rowe, E. Pujade-Lauraine (2020)Final overall survival (OS) results from SOLO2/ENGOT-ov21: A phase III trial assessing maintenance olaparib in patients (pts) with platinum-sensitive, relapsed ovarian cancer and a BRCA mutation.
Journal of Clinical Oncology, 38
J. Litton, H. Rugo, J. Ettl, S. Hurvitz, A. Gonçalves, Kyung-Hun Lee, L. Fehrenbacher, R. Yerushalmi, L. Mina, Miguel Martín, H. Roché, Y. Im, R. Quek, D. Markova, I. Tudor, A. Hannah, W. Eiermann, J. Blum (2018)Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation
The New England Journal of Medicine, 379
(2019)Cancer trials ireland opens study to enable upfront and streamlined germline and somatic BRCA1/2 mutation testing in women with ovarian cancer
J. McHugh, G. Offiah, S. Daly, N. Beltagi, M. Barry, S. O'Reilly, T. McVeigh (2021)Postgraduate training in Cancer Genetics—a cross-specialty survey exploring experience of clinicians in Ireland
Irish Journal of Medical Science, 191
Jenny Lin, R. Sharaf, Rachel Saganty, Danyal Ahsan, J. Feit, Andrea Khoury, Hannah Bergeron, E. Chapman-Davis, E. Cantillo, K. Holcomb, S. Blank, Ying Liu, Charlene Thomas, P. Christos, D. Wright, S. Lipkin, K. Offit, M. Frey (2021)Achieving universal genetic assessment for women with ovarian cancer: Are we there yet? A systematic review and meta-analysis.
A. George, Daniel Riddell, S. Seal, S. Talukdar, S. Mahamdallie, Elise Ruark, V. Cloke, I. Slade, Z. Kemp, M. Gore, Ann Strydom, Susana Banerjee, H. Hanson, N. Rahman (2016)Implementing rapid, robust, cost-effective, patient-centred, routine genetic testing in ovarian cancer patients
Scientific Reports, 6
C. Seoighe, A. Bracken, P. Buckley, P. Doran, R. Green, Sandra Healy, D. Kavanagh, E. Kenny, M. Lawler, M. Lowery, D. Morris, Darrin Morrissey, J. O’Byrne, D. Shields, Owen Smith, C. Steward, B. Sweeney, W. Kolch (2020)The future of genomics in Ireland – focus on genomics for health
HRB Open Research, 3
J. Barwell, K. Snape, S. Wedderburn (2019)The new genomic medicine service and implications for patients .
Clinical medicine, 19 4
R. Waterston, E. Lander, J. Sulston (2002)On the sequencing of the human genome
Proceedings of the National Academy of Sciences of the United States of America, 99
K. Moore, N. Colombo, G. Scambia, Byoung-Gie Kim, A. Oaknin, M. Friedlander, A. Lisyanskaya, A. Floquet, A. Leary, G. Sonke, C. Gourley, Susana Banerjee, A. Oza, A. González-Martín, C. Aghajanian, W. Bradley, C. Mathews, Joyce Liu, E. Lowe, R. Bloomfield, P. DiSilvestro (2018)Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
The New England Journal of Medicine, 379
Me. Rumford, M. Lythgoe, I. McNeish, H. Gabra, L. Tookman, N. Rahman, A. George, J. Krell (2020)Oncologist-led BRCA ‘mainstreaming’ in the ovarian cancer clinic: A study of 255 patients and its impact on their management
Scientific Reports, 10
Nicola Scott, J. O'Sullivan, K. Ásgeirsson, D. Macmillan, E. Wilson (2020)Changing practice: moving to a specialist nurse-led service for BRCA gene testing.
British journal of nursing, 29 10
R. Coleman, A. Oza, D. Lorusso, C. Aghajanian, A. Oaknin, A. Dean, N. Colombo, J. Weberpals, A. Clamp, G. Scambia, A. Leary, Robert Holloway, M. Gancedo, P. Fong, J. Goh, D. O’Malley, D. Armstrong, J. García-Donas, E. Swisher, A. Floquet, G. Konecny, I. McNeish, C. Scott, T. Cameron, L. Maloney, J. Isaacson, S. Goble, C. Grace, T. Harding, M. Raponi, James Sun, K. Lin, H. Giordano, J. Ledermann (2017)Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial
The Lancet, 390
D. Tan, S. Kaye (2015)Chemotherapy for Patients with BRCA1 and BRCA2-Mutated Ovarian Cancer: Same or Different?
American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting
(2016)Chief medical officer's summary, in annual report of the chief medical officer-generation genome
Andrew Lee, A. Cunningham, K. Kuchenbaecker, N. Mavaddat, D. Easton, A. Antoniou (2013)BOADICEA breast cancer risk prediction model: updates to cancer incidences, tumour pathology and web interface
British Journal of Cancer, 110
F. Lalloo, J. Varley, D. Ellis, A. Moran, L. O'dair, P. Pharoah, D. Evans (2003)Prediction of pathogenic mutations in patients with early-onset breast cancer by family history
The Lancet, 361
I. Ray-Coquard, P. Pautier, S. Pignata, D. Pérol, A. González-Martín, R. Berger, K. Fujiwara, I. Vergote, N. Colombo, J. Mäenpää, F. Selle, J. Sehouli, D. Lorusso, E. Alía, A. Reinthaller, S. Nagao, C. Lefeuvre-Plesse, U. Canzler, G. Scambia, A. Lortholary, F. Marmé, P. Combe, N. Gregorio, M. Rodrigues, P. Buderath, C. Dubot, A. Burges, B. You, E. Pujade-Lauraine, P. Harter (2019)Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer.
The New England journal of medicine, 381 25
R. Coleman, G. Fleming, M. Brady, E. Swisher, K. Steffensen, M. Friedlander, A. Okamoto, K. Moore, Noa (Ben-Baruch), T. Werner, N. Cloven, A. Oaknin, P. DiSilvestro, M. Morgan, J. Nam, C. Leath, S. Nicum, A. Hagemann, R. Littell, D. Cella, S. Baron-Hay, J. García-Donas, M. Mizuno, K. Bell-McGuinn, D. Sullivan, B. Bach, Sudipta Bhattacharya, C. Ratajczak, P. Ansell, M. Dinh, C. Aghajanian, M. Bookman (2019)Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer.
The New England journal of medicine
J. Hoskovec, R. Bennett, Meghan Carey, J. DaVanzo, Michael Dougherty, Michael Dougherty, Susan Hahn, B. LeRoy, S. O’Neal, J. Richardson, C. Wicklund (2018)Projecting the Supply and Demand for Certified Genetic Counselors: a Workforce Study
Journal of Genetic Counseling, 27
R. Manchanda, Shreeya Patel, V. Gordeev, A. Antoniou, Shantel Smith, Andrew Lee, J. Hopper, R. MacInnis, C. Turnbull, S. Ramus, S. Gayther, P. Pharoah, U. Menon, I. Jacobs, R. Legood (2018)Cost-effectiveness of Population-Based BRCA1, BRCA2, RAD51C, RAD51D, BRIP1, PALB2 Mutation Testing in Unselected General Population Women
JNCI: Journal of the National Cancer Institute, 110
T. McVeigh, K. Sweeney, M. Kerin, D. Gallagher (2016)A qualitative analysis of the attitudes of Irish patients towards participation in genetic-based research
Irish Journal of Medical Science (1971 -), 185
L. Bradley, S. Lynch (2020)Dying to see you? Deaths on a clinical genetics waiting list in the Republic of Ireland; what are the consequences?
Journal of Community Genetics, 12
Digital Delivery of Information About Genetic Testing for Breast Cancer (BRCA-DIRECT)
M. Kentwell, Eryn Dow, Y. Antill, C. Wrede, O. Mcnally, E. Higgs, A. Hamilton, S. Ananda, Geoffrey Lindeman, Clare Scott (2017)Mainstreaming cancer genetics: A model integrating germline BRCA testing into routine ovarian cancer clinics.
Gynecologic oncology, 145 1
T. McVeigh, N. Cody, C. Carroll, M. Duff, M. Farrell, L. Bradley, D. Gallagher, T. Mcdevitt, A. Green (2017)Recurrent large genomic rearrangements in BRCA1 and BRCA2 in an Irish case series.
Cancer genetics, 214-215
M Robson (2017)10.1056/NEJMoa1706450
N Engl J Med, 377
(2019)Genetic service delivery models: exploring approaches to care for families with hereditary cancer risk
James Morrow (2004)The University of Washington
Math Horizons, 12
A. González-Martín, B. Pothuri, I. Vergote, R. Christensen, W. Graybill, M. Mirza, C. Mccormick, D. Lorusso, P. Hoskins, G. Freyer, K. Baumann, K. Jardon, A. Redondo, R. Moore, C. Vulsteke, R. O’Cearbhaill, B. Lund, F. Backes, P. Barretina-Ginesta, Ashley Haggerty, M. Rubio-Pérez, M. Shahin, G. Mangili, W. Bradley, I. Bruchim, K. Sun, I. Malinowska, Yong Li, D. Gupta, B. Monk (2019)Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.
The New England journal of medicine
E. Pujade-Lauraine, J. Ledermann, F. Selle, V. Gebski, R. Penson, A. Oza, J. Korach, T. Huzarski, A. Poveda, S. Pignata, M. Friedlander, N. Colombo, P. Harter, K. Fujiwara, I. Ray-Coquard, Susana Banerjee, Joyce Liu, E. Lowe, R. Bloomfield, P. Pautier (2017)Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial.
The Lancet. Oncology, 18 9
S. Yadav, A. Reeves, Sarah Campian, Amy Sufka, D. Zakalik (2017)Preoperative genetic testing impacts surgical decision making in BRCA mutation carriers with breast cancer: a retrospective cohort analysis
Hereditary Cancer in Clinical Practice, 15
Monica Penon-Portmann, Jiyoo Chang, Mira Cheng, Joseph Shieh (2019)Genetics Workforce: Distribution of Genetics Services and Challenges to Healthcare in California
Genetics in medicine : official journal of the American College of Medical Genetics, 22
Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations
K. Gonzalez, Katie Noltner, C. Buzin, D. Gu, Cindy Wen-Fong, V. Nguyen, Jennifer Han, K. Lowstuter, J. Longmate, S. Sommer, J. Weitzel (2009)Beyond Li Fraumeni Syndrome: clinical characteristics of families with p53 germline mutations.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 27 8
In the Republic of Ireland (ROI), BRCA1/BRCA2 genetic testing has been traditionally undertaken in eligible individuals, after pre-test counselling by a Clinical Geneticist/Genetic Counsellor. Clinical Genetics services in ROI are poorly resourced, with routine waiting times for appointments at the time of this pilot often extending beyond a year. The consequent prolonged waiting times are unacceptable where therapeutic decision-making depends on the patient’s BRCA status. “Mainstreaming” BRCA1/BRCA2 testing through routine oncology/surgical clinics has been implemented successfully in other centres in the UK and internationally. We aimed to pilot this pathway in three Irish tertiary centres. A service evaluation project was undertaken over a 6-month period between January and July 2017. Eligible patients, fulfilling pathology and age-based inclusion criteria defined by TGL clinical, were identified, and offered constitutional BRCA1/BRCA2 testing after pre-test counselling by treating clinicians. Tests were undertaken by TGL Clinical. Results were returned to clinicians by secure email. Onward referrals of patients with uncertain/pathogenic results, or suspicious family histories, to Clinical Genetics were made by the treating team. Surveys assessing patient and clinician satisfaction were sent to participating clinicians and a sample of participating patients. Data was collected with respect to diagnostic yield, turnaround time, onward referral rates, and patient and clinician feedback. A total of 101 patients underwent diagnostic germline BRCA1/BRCA2 tests through this pathway. Pathogenic variants were identified in 12 patients (12%). All patients in whom variants were identified were appropriately referred to Clinical Genetics. At least 12 additional patients with uninformative BRCA1/BRCA2 tests were also referred for formal assessment by Clinical Geneticist or Genetic Counsellor. Issues were noted in terms of time pressures and communication of results to patients. Results from a representative sample of participants completing the satisfaction survey indicated that the pathway was acceptable to patients and clinicians. Mainstreaming of constitutional BRCA1/BRCA2 testing guided by age- and pathology-based criteria is potentially feasible for patients with breast cancer as well as patients with ovarian cancer in Ireland.
Familial Cancer – Springer Journals
Published: Apr 1, 2023
Keywords: BRCA1; BRCA2; Hereditary Breast and Ovarian cancer; King syndrome; Breast cancer; Ovarian cancer; Mainstreaming; Cancer genetics; Oncogenetics; Cancer genomics
Access the full text.
Sign up today, get DeepDyve free for 14 days.